Abstrak
Periodontal inflammation is a periodontal disorder of high prevalence in the population. According to the Data Center, Ministry of Health of The Republic of Indonesia, periodontal disorder ranks on the 8 th position among the 10 main diseases of outpatients in the general hospitals. 1 The severity of the disease is determined by the degree of clinical periodontal status. The periodontal status is influenced by local factors such as accumulation of plaque and calculus, and systemic factors such as hormonal imbalance, diabetes mellitus, nutrition, genetic, make up and the use of drugs. Removing calculus (scaling) as non-surgical periodontal therapy improves clinical periodontal status. 1, 2 The systemic condition primarily affects tissue defense mechanism/immunity which is determined by the periodontal immune response and can be evaluated by looking at local or systemic cellular immune response. The phagocytic function of polymorphonuclear leucocytes (PMN) represents systemic immune mechanism that is clinically important to determine immunity against infection. 3, 4, 5 The main mediator of periodontal inflammation is IL-1. According to the Committee on Research, Science and Therapy, The American Academy of Periodontology, a periodontal infection, although minor, can affect the general health via systemic immune response. 6 In vitro studies showed that cytokines (IL-1, TNF, and IFN) cause inhibition of insulin synthesis as well as insulin secretion, and therefore damaging  cells of the pancreas. 7, 8 It is estimated, from 1994 until 2010, that the number of diabetic patients in the world population will increase two-fold reaching 239 million. 9 Based on Indonesia's population growth tendencies today and according to the 2000 Diabetes Atlas (International Diabetes Federation), the number of people above 20 years of age in year 2020, is estimated to be 178 million, so that those who will be suffering from diabetes mellitus is estimated to be 8.2 million.
1 Type 2 diabetes is suffered by 90% of diabetic patients. This type were usually detected at the age of 35-40 years. 10 Hyperglycemia activates diacyl glycerol (DAG)-proteinkinase C (PKC), thus increasing prostaglandin E2 (PGE2) and cytokine expressions that induce inflammation and periodontal tissue destruction processes. 11, 12 In Indonesia, studies concerning the effect of scaling as non-surgical periodontal therapy on systemic immune response IL-1 level and phagocytotic function of PMN and control of blood glucose level in diabetic patients has never been carried out. Therefore, to improve the quality of care of diabetic patients, we conducted this study in order to give a sound scientific basis to establish Standard Operating Procedure of the management of periodontal diseases in diabetic patients.
The objective of this study was to evaluate the effect of scaling to immune response, and blood glucose level in controlled and uncontrolled type 2 diabetic patients.
METHODS
This was a clinical study on 60 controlled-diabetes mellitus (CDM) subjects and 60 uncontrolled-diabetes mellitus (UCDM) subjects in the Metabolic Endocrinology Clinic, Cipto Mangunkusumo Hospital Jakarta. The patients were on standard diet treatment and Oral Hypoglicemic Agents (OHA). This study was conducted from 2 nd April through 20 th August 2003. Ethical clearance was obtained from the Committee of the Medical Research Ethics of the Faculty of medicine, University of Indonesia. The subjects were divided into two groups, the intervention group and non-intervention group. Scaling was done in all intervension cases. Both groups were selected by simple random sampling. In this study we analyzed blood glucose and HbA1c levels, PMN phagocytotic function, and IL-1 level on both groups. Analysis was performed before intervention and 6 weeks after intervention. Paired t-test was used to compare the parameters before and after scaling, in CDM and UCDM subjects without and with intervention. The statistical analysis was performed using a computer with Stata 7.0 software. Table 1 shows a significant decrease in IL-1 level in UCDM intervention group as much as 7.67 pg/mL (P= 0.000), which was more than in the non-intervention group (3.15 pg/mL). Moreover, in the intervention group, scaling increased phagocytotic function of PMN significantly (9.95%, P= 0.005), while in the non-intervention group the increase of phagocytotic function was not significant (2.9%, P= 0.335).
RESULTS

Effect of Scaling on Immune Response
Effect of Scaling on Blood Glucose Level
After 6 weeks of scaling in both CDM and UCDM groups, the fasting blood glucose level, 2 hours postprandial blood glucose level, and HbA1c level were all decreased. However, the increase was not significant except for the decrease of 0.54% in HbA1c among UCDM group (P= 0.000).
DISCUSSION
Although there was a decreased in IL-1 level in the group without intervention (Table 1 ), but decrease was supposed to be an individual response to the test conducted (Hawthorne effect). 12 The accumulation of bacterial plaque was the main local risk factor of periodontal inflammation. In this study, scalling as non-surgical periodontal therapy showed a decrease in IL-1 level and increased phagocytotic function of PMN significantly after scaling (P < 0.05). Interleukine-1 is the main mediator of periodontal inflammation, and the phagocytic function of PMN represents systemic immune mechanism that is clinically important to determine immunity against infection. Although the number of PMN is increased in periodontal infection, leucotoxin and protease produced by periodontal pathogen (Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis) will induce chemotactic and phagocytotic defects; therefore causing decreased PMN phagocytic function. [3] [4] [5] In term of IL-1 level, our finding was consistent with the finding of Gamonal et al. who studied local IL-1 level in the gingival crevicular fluid and found that IL-1 level was correlated to periodontal status because the absence of calculus and bacterial plaque decreased the antigenic stimulation and thus decreased chemokine production.
14 After 6 weeks of non-surgical treatment (Table 2 ), the fasting blood glucose level, 2 hours postprandial blood glucose level and HbA1c level were all decreased; however, the decrease was not statistically significant except for decreased HBA1c level among UCDM group (P= 0.000).
The reason of the statistically non significant decrease might be due to the many factors that affected blood glucose level, i.e. lipid level, obesity, hypertension, insulin level, inactivity, stress, smoking, age, etc. 15 This decrease was in accordance with the finding of Fu et al. that showed controlling periodontal inflammation improved metabolism of type 2 diabetic patients. 16 Previous studies showed that cytokines directly stimulated iNOS (inducible nitric oxide synthase) expression and increased NO (nitric oxide) production by  cells, and then NO indirectly damaged  cells. Cytokines also stimulated iNOS expression through non-endocrine cells (macrophages and endothelial cells), and the NO produced can cause damage to  cells. Furthermore, cytokines also affected tyrosine kinase receptor function and caused insulin resistance. 7, 8 Control of inflammation was shown to decrease cytokine level so that iNOS stimulation and NO production by  cells was decreased resulting in decreased  cells damage and stimulated insulin secretion. 11 In diabetes mellitus, advanced glycosilation end product (AGE) is bound to monocytes, and thus increasing chemotaxis, IL-1  and TNF levels, and activates macrophages and osteoclasts. Moreover the binding of AGE to the endothelial cells cause cell function changes, vascular lesion and vasocontriction. Hyperglycemia activates DAG-PKC, thus increasing PGE2 and cytokine expression, 11 while control of periodontal inflammation will decrease chemotaxis and cytokine expression.
The significant decrease of HbA1c in UCDM in this study was consistent with previous finding reported that the decrease of HbA1c level occurred within 3 weeks after one week achieving a controlled fasting blood glucose level, 17 and it was consistent with the finding of Rodrigues et al. that showed that 3 months after local treatment there was a significant decrease in HbA1c level (P < 0.05) and insignificant decrease in fasting blood glucose level (P > 0.05). 18 This study suggests that scaling as non-surgical periodontal therapy resulted in decreased blood glucose level in type 2 diabetic patients, and can be used to overcome the problems of diabetic patients with periodontal disease. Therefore, we recommend that especially for patients suffering from DM to maintain their periodontal health by performing plaque and calculus control periodically to reduce the risk factors affecting type 2 DM, and at the same time to control their blood glucose level.
In conclusion, scaling increased periodontal status, decreased IL-1 level, and increased phagocytic function significantly. Furthermore, scaling decreased fasting and 2 hours postprandial blood glucose levels and also HbA1c level, but the decreases were not statistically significant except for the decrease in HbA1c level in UCDM group.
